Hong Kong's three major stock indexes all declined by midday trading on August 12. The Hang Seng Index dropped 1.17% to 25,352.13, the Hang Seng Tech Index also fell 1.17%, and the Hang Seng China Enterprises Index declined 1.27%.
Technology stocks broadly declined, with Bilibili, NetEase, and Alibaba each falling over 3%. The optical communications sector was a standout performer, with Zhongji Innolight surging over 7%. The cloud computing sector led losses, with Kingdee International dropping more than 7%. The innovative drug sector weakened, with Hengrui Medicine falling 2%.
Why is the optical communications sector surging?
Zhongji Innolight rose more than 7%. JPMorgan Chase increased its stake in the company's H-shares from 14.93% to 15.60% on August 6, purchasing at an average price of 1,151.9056 Hong Kong dollars. According to Hong Kong Exchange disclosure data, JPMorgan has added to its position multiple times within just one week. Additionally, U.S. optical communications giant Lumentum reported its fiscal 2026 fourth-quarter earnings after the market close on August 11, significantly exceeding market expectations. The company's fourth-quarter net revenue surged 109% year-over-year to $1.01 billion, while non-GAAP adjusted earnings per share skyrocketed 267% to $3.23.
What's behind the cloud computing sector's decline?
Kingdee International fell over 7%. The company announced its first-half 2026 results yesterday, which showed a 13.6% year-over-year revenue increase to approximately 3.625 billion yuan and a return to profitability. However, CFO Lin Bo revealed during the August 12 earnings conference that the company has invested in several large model companies this year. Subsequent stock price fluctuations or value changes from potential listings of these companies will significantly impact the company's book profits. The company emphasized that investors should focus on adjusted profit (116 million yuan) to reflect true operating conditions. This suggests that the reported "return to profitability" relies partly on one-time investment gains rather than pure core business improvement, raising concerns about earnings quality.
Why is the innovative drug sector weakening?
Hengrui Medicine fell 2%. CICC believes the trend for the innovative drug industry is clear and remains attractive for allocation after the current volatility. Upcoming key data releases at the ESMO annual conference, new blockbuster BD deals, and technological breakthroughs are expected to serve as important catalysts for the sector. For investors bullish on the long-term development of the innovative drug industry, innovative drug ETFs like E Fund provide a convenient channel for one-click allocation to core assets in the innovative drug and CXO supply chain. Given the sector's high volatility, investors are advised to adopt a phased investment or long-term allocation strategy.
Comments